We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
-6.57%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
–
AUM
$2.24B
AUM Growth
-$333M
Cap. Flow
-$6.09M
Cap. Flow %
-0.27%
Top 10 Hldgs %
100%
Holding
11
New
–
Increased
1
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
EVLO
Evelo Biosciences, Inc. Common Stock
EVLO
+$9

Top Sells

Rank Stock Value
1
SANA icon
Sana Biotechnology
SANA
+$5.47M
2
CDAK
Codiak BioSciences, Inc. Common Stock
CDAK
+$618K
3
SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
+$7

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$1.57B 69.88%
12,886,743
– –
SANA icon
2
Sana Biotechnology
SANA
$885M
$198M 8.85%
33,290,018
-949,000
-3% -$5.47M
OMGA
3
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$164M 7.3%
29,225,579
– –
MCRB icon
4
Seres Therapeutics
MCRB
$48.1M
$111M 4.94%
1,155,852
– –
FHTX icon
5
Foghorn Therapeutics
FHTX
$285M
$89.2M 3.98%
12,674,120
– –
DNLI icon
6
Denali Therapeutics
DNLI
$3.67B
$77.3M 3.45%
2,619,968
– –
SGTX
7
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$18M 0.8%
797,720
-1
-0% -$7
EVLO
8
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$8.19M 0.37%
2,521,369
+3
+0% +$9
AXLA
9
DELISTED
Axcella Health Inc. Common Stock
AXLA
$6.39M 0.29%
1,170,062
– –
SYRS
10
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.13M 0.14%
993,848
– –
CDAK
11
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
– –
-3,540,636
Closed -$618K

Similar funds

AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
BI
Bramshill Investments Naples, Florida $1.16B AUM 0.86% 1-Year Est. Return
SCP
Sandhill Capital Partners Buffalo, New York $1.16B AUM 12.37% 1-Year Est. Return
SFG
SNS Financial Group Minneapolis, Minnesota $1.16B AUM 13.88% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.16B AUM 25.7% 1-Year Est. Return
AMI
Amica Mutual Insurance Providence, Rhode Island $1.16B AUM 21.34% 1-Year Est. Return
FFP
FourThought Financial Partners Venice, Florida $1.16B AUM 24.95% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Flagship Pioneering's Q2 2023 Portfolio in Review

As of Q2 2023, Flagship Pioneering held 11 positions worth $2.24B, down 13% from $2.57B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Flagship Pioneering's Q2 2023 filing shows 1 increased, 2 reduced and 1 closed positions. The largest sale was Sana Biotechnology, an estimated $5.47M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Flagship Pioneering added most to Evelo Biosciences, Inc. Common Stock in Q2 2023, an estimated $9 increase.
  • Flagship Pioneering's biggest Q2 2023 reduction was Sana Biotechnology, cutting an estimated $5.47M.
  • Flagship Pioneering fully exited Codiak BioSciences, Inc. Common Stock in Q2 2023, selling an estimated $618K.
  • Flagship Pioneering's ten largest holdings make up 100% of its $2.24B portfolio in Q2 2023.
  • Flagship Pioneering opened 0 new positions and closed 1 in Q2 2023.
  • Flagship Pioneering's portfolio value fell 13% quarter-over-quarter to $2.24B.

Based on Flagship Pioneering's 13F filing for Q2 2023, filed 14 Aug 2023.